Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/28/2025

Treatment of Pseudomonas aeruginosa Infections

Antimicrobial Activity and Guidelines

  • The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines do not recommend tigecycline for Pseudomonas infections due to its inadequate activity 1

Clinical Implications and Alternative Treatments

  • For carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections, ESCMID guidelines suggest therapy with ceftolozane-tazobactam if active in vitro, rather than tigecycline 1
  • For non-severe CRPA infections, old antibiotics should be chosen from among in vitro active agents according to the source of infection 1
  • The FDA has issued a Boxed Warning for tigecycline, recommending consultation with infectious disease specialists when considering its use 2
  • For carbapenem-resistant Pseudomonas aeruginosa (CRPA), ESCMID guidelines recommend ceftolozane-tazobactam if active in vitro for severe infections 1
  • For non-severe infections, use of old antibiotics that show in vitro activity is recommended by ESCMID guidelines 1
  • Antipseudomonal drugs that may be effective include carbapenems, cephalosporins (ceftazidime, cefepime), fluoroquinolones, aminoglycosides, and polymyxins, depending on susceptibility patterns 1